LB Pharmaceuticals Launches Phase 3 NOVA-2 Trial for Schizophrenia Treatment LB-102

LB Pharmaceuticals Inc., a late-stage biopharmaceutical company focused on developing treatments for neuropsychiatric disorders, has announced the initiation of its pivotal Phase 3 clinical trial, known as NOVA-2, to evaluate the effectiveness and safety of its investigational drug LB-102 for the treatment of schizophrenia. The launch of this late-stage trial represents a major step forward in the company’s efforts to bring a new treatment option to patients suffering from schizophrenia, a serious and chronic mental health disorder that affects millions of people worldwide.

LB-102 is a novel, once-daily oral medication currently being developed for the treatment of schizophrenia and other neuropsychiatric conditions such as bipolar depression and major depressive disorder. The drug works by targeting specific receptors in the brain, including dopamine D2 and D3 receptors and serotonin 5HT-7 receptors. By selectively blocking these receptors, the drug aims to reduce symptoms of schizophrenia while minimizing common side effects associated with existing antipsychotic medications. The company believes LB-102 has the potential to become the first benzamide class drug approved for schizophrenia treatment in the United States.

The Phase 3 NOVA-2 trial is designed to enroll approximately 460 patients who are experiencing acute exacerbation of schizophrenia. The study will be conducted across approximately 25 clinical sites in the United States. This trial will be randomized, double-blind, and placebo-controlled, which means neither the patients nor the researchers will know who is receiving the actual drug or the placebo during the study period. This type of study design is considered the gold standard for evaluating the effectiveness and safety of new medications.

Participants in the NOVA-2 trial will be randomly assigned to receive either 50 mg of LB-102, 100 mg of LB-102, or a placebo once daily for six weeks. The main goal of the study is to measure improvement in schizophrenia symptoms using a standard clinical tool known as the Positive and Negative Syndrome Scale (PANSS). The primary endpoint of the study is the change in PANSS total score from baseline to Week 6. This scale is widely used in schizophrenia research and measures positive symptoms such as hallucinations and delusions, negative symptoms such as lack of motivation and emotional expression, and general psychopathology.

In addition to the primary endpoint, the trial will also evaluate several secondary endpoints. These include improvements in overall disease severity using the Clinical Global Impression-Severity (CGI-S) scale, changes in positive and negative symptoms measured by PANSS subscales, cognitive performance, and personal and social functioning using the Personal and Social Performance (PSP) scale. The study will also monitor the safety and tolerability of LB-102 to ensure that the medication does not cause significant adverse effects.

According to LB Pharmaceuticals’ leadership, the initiation of the NOVA-2 trial is an important milestone for the company and reflects the progress made during earlier clinical trials. The company previously conducted a Phase 2 trial known as NOVA-1, in which LB-102 demonstrated statistically significant improvement in schizophrenia symptoms compared to placebo. The Phase 2 study also showed rapid onset of action, with patients experiencing improvement as early as the first week of treatment, and sustained benefits throughout the duration of the trial.

One of the major concerns with existing schizophrenia medications is the side effect profile, which can include movement disorders such as extrapyramidal symptoms (EPS), akathisia (restlessness), sedation, and gastrointestinal problems. However, in earlier studies, LB-102 showed a potentially favorable safety profile with low rates of movement-related side effects, minimal sedation, and fewer gastrointestinal issues. Researchers also observed improvements in negative symptoms and cognitive performance, which are areas where many current treatments are less effective.

Schizophrenia is a complex mental disorder that affects how a person thinks, feels, and behaves. It is typically characterized by positive symptoms such as hallucinations and delusions, negative symptoms such as reduced emotional expression and lack of motivation, and cognitive symptoms such as difficulty concentrating and memory problems. While current treatments can help manage positive symptoms, many patients continue to struggle with negative and cognitive symptoms, which significantly affect their ability to function in daily life. Because of this, there is a strong need for new treatments that can address all aspects of the disorder.

In addition to the NOVA-2 trial, the company also plans to initiate a large open-label extension study that will enroll approximately 900 patients. Patients who complete the NOVA-2 trial will be eligible to continue into the extension study, where they will receive LB-102 for a longer period of time. This study will help researchers evaluate the long-term safety of the drug and further study its effects on negative symptoms and cognitive performance. The open-label study will also include new patients who were not part of the NOVA-2 trial.

LB Pharmaceuticals expects to release topline results from the NOVA-2 Phase 3 trial in the second half of 2027. If the results are positive, the data from this trial, along with results from the Phase 2 NOVA-1 trial and the open-label extension study, could support regulatory approval of LB-102 in the United States.

The development of LB-102 represents an important step in the field of psychiatric medicine, where innovation has been relatively slow compared to other areas of healthcare. Many currently available antipsychotic medications were developed decades ago, and while they are effective for some patients, they often come with significant side effects and limitations. A new medication that can effectively treat schizophrenia symptoms while maintaining a good safety and tolerability profile would represent a significant advancement in treatment options.

The company believes that LB-102 could become an important treatment option for schizophrenia and potentially for other neuropsychiatric disorders as well. By targeting multiple receptors involved in mood, cognition, and behavior, the drug aims to provide a balanced clinical benefit across multiple symptom domains.